Literature DB >> 9305991

Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel.

F S Seibert1, Y Jia, C J Mathews, J W Hanrahan, J R Riordan, T W Loo, D M Clarke.   

Abstract

Since little is known about the contribution to function of the N-terminal cytoplasmic loops (CL1, residues 139-194; CL2, residues 242-307) of cystic fibrosis transmembrane conductance regulator (CFTR), all nine point mutations identified in CLs 1 and 2 from patients with cystic fibrosis were reconstructed in the expression vector pcDNA3-CFTR and expressed transiently in COS-1 and HEK-293 cells and stably in Chinese hamster ovary (CHO) cells. Four amino acid substitutions retarded production of mature, fully glycosylated CFTR, suggesting that misprocessing of the channel causes the disease symptoms in the affected patients. Protein maturation could not be promoted by cell culture conditions of reduced temperature (26 degrees C). When properly processed mutants were evaluated for functional defects by the iodide efflux method, the G178R- and E193K-CFTR-expressing cell lines showed impaired anion translocation activities. Patch-clamp studies of single channels revealed that E193K variants had a significantly decreased open probability, which resulted from an increase in the mean closed time of the channels. This contrasted with a previous study of disease-associated point mutations in CL3 that mainly affected the mean open time. None of the maturation-competent CL 1 and 2 mutants had altered conductance. Thus, the N-terminal CLs appear not to contribute to the anion translocation pathway of CFTR; rather, mutations in CL1 can impede transition to the open state. Interestingly, the ability of the non-hydrolyzable ATP analogue adenylyl imidodiphosphate (AMP-PNP) to lock the channel into open bursts was abolished by the I148T and G178R amino acid substitutions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305991     DOI: 10.1021/bi9712652

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  26 in total

1.  Intragenic suppressing mutations correct the folding and intracellular traffic of misfolded mutants of Yor1p, a eukaryotic drug transporter.

Authors:  Silvere Pagant; John J Halliday; Christos Kougentakis; Elizabeth A Miller
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

2.  Mapping of interdomain interfaces required for the functional architecture of Yor1p, a eukaryotic ATP-binding cassette (ABC) transporter.

Authors:  Silvere Pagant; Ethan Y Brovman; John J Halliday; Elizabeth A Miller
Journal:  J Biol Chem       Date:  2008-07-21       Impact factor: 5.157

3.  Aberrant CFTR-dependent HCO3- transport in mutations associated with cystic fibrosis.

Authors:  J Y Choi; D Muallem; K Kiselyov; M G Lee; P J Thomas; S Muallem
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

4.  Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin.

Authors:  Carlos M Farinha; Margarida D Amaral
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

5.  Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2.

Authors:  Surtaj H Iram; Susan P C Cole
Journal:  J Biol Chem       Date:  2010-12-20       Impact factor: 5.157

6.  Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.

Authors:  Antonella Caputo; Alexandre Hinzpeter; Emanuela Caci; Nicoletta Pedemonte; Nicole Arous; Marco Di Duca; Olga Zegarra-Moran; Pascale Fanen; Luis J V Galietta
Journal:  J Pharmacol Exp Ther       Date:  2009-06-02       Impact factor: 4.030

7.  NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR.

Authors:  Voula Kanelis; Rhea P Hudson; Patrick H Thibodeau; Philip J Thomas; Julie D Forman-Kay
Journal:  EMBO J       Date:  2009-11-19       Impact factor: 11.598

8.  Assessing the Disease-Liability of Mutations in CFTR.

Authors:  Claude Ferec; Garry R Cutting
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

9.  Molecular models of human P-glycoprotein in two different catalytic states.

Authors:  Jean-Paul Becker; Grégoire Depret; Françoise Van Bambeke; Paul M Tulkens; Martine Prévost
Journal:  BMC Struct Biol       Date:  2009-01-22

10.  Interplay between ER exit code and domain conformation in CFTR misprocessing and rescue.

Authors:  Gargi Roy; Elaine M Chalfin; Anita Saxena; Xiaodong Wang
Journal:  Mol Biol Cell       Date:  2009-12-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.